Missouri Records $125M in Cannabis Sales for March

1.3 min readPublished On: April 17th, 2024By

LOS ANGELES- Missouri has achieved a new milestone in cannabis sales, registering a record-breaking $124.7 million in combined medical and adult-use cannabis sales for March, as reported by the Division of Cannabis Regulation (DCR). This figure surpasses the previous records, highlighting a significant uptick in consumer spending within the state’s cannabis markets.

In detail, adult-use cannabis sales contributed $108.7 million, marking a record high for the sector, while medical cannabis accounted for $16 million. Both sectors saw month-over-month increases, signaling a robust demand across the board. This resurgence in adult-use sales comes after a dip in the early months of the year, following a high in November.

Since the commencement of sales tracking in December 2022, Missouri has amassed a total of $2.29 billion in cannabis revenue, with these figures stemming just one month before the official launch of the adult-use market in 2023. Although medical cannabis sales have shown a declining trend, adult-use sales have consistently expanded, reflecting shifting consumer patterns and broader acceptance following legalization.

Additionally, in line with Missouri’s voter-approved cannabis legalization amendment, nearly 100,000 cannabis convictions were expunged last year. The amendment mandates the expungement of all misdemeanor and many felony cannabis convictions, with exceptions for those currently incarcerated or under supervision.

Missouri’s progressive steps in cannabis legalization and the subsequent economic benefits underscore its pioneering role in the Midwest’s cannabis reform landscape, following its 2022 amendment that made it the 21st state to legalize cannabis. This development not only enhances state revenues but also represents significant shifts in legal and social perspectives towards cannabis use and regulation.

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!